Bristol Myers Squibb

News

BMS grabs key approval for Reblozyl in MDS

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

BMS feels the pain of Revlimid erosion, cutting forecasts

Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.

News

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica

News

BMS’ Sotyktu cleared for NHS use in psoriasis

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.

News

BMS joins Merck in challenge to Medicare price negotiation

Bristol-Myers Squibb has filed a lawsuit against the US government that aims to block the drug price negotiation elements of the Inflation Reduction Act (IRA), joining fel

BMS grabs key approval for Reblozyl in MDS

AZ and BMS resolve checkpoint inhibitor patent disputes

BMS feels the pain of Revlimid erosion, cutting forecasts

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

BMS’ Sotyktu cleared for NHS use in psoriasis

BMS joins Merck in challenge to Medicare price negotiation

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks